Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Want to cut your energy bills? Here’s how five experts are doing it 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
BOSTON, Feb. 28, 2017 -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by metabolic diseases including type 2 diabetes and obesity, announced today that Thomas Hughes, Ph.D., President and Chief Executive Officer of Zafgen, will present at two upcoming investor conferences:
- The Cowen and Company 37th Annual Health Care Conference in Boston, MA on Tuesday, March 7, 2017 at 10:00 a.m. ET; and
- The 29th Annual Roth Conference in Dana Point, CA on Tuesday, March 14, 2017 at 12:00 p.m. PT.
A live audio webcast and replay of both presentations will be available through the Events and Presentations page of the Investors section of the Company's website (www.zafgen.com) for 90 days following the conclusion of the live event.
About Zafgen
Zafgen (Nasdaq:ZFGN) is a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by metabolic diseases including type 2 diabetes and obesity. Zafgen is focused on developing novel therapeutics that treat the underlying biological mechanisms of metabolic diseases through the MetAP2 pathway. Zafgen has pioneered the study of MetAP2 inhibitors in both common and rare forms of obesity. Zafgen's lead product candidate is ZGN-1061, which is a novel, first-in-class, twice-weekly subcutaneous injection. Zafgen aspires to improve the lives of patients through targeted treatments and has assembled a team accomplished in bringing therapies to patients affected by metabolic diseases.
Investor Relations Contact: Argot Partners Investor Relations Laura Perry or Glenn Garmont 212-600-1902 [email protected] [email protected]
